Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore

Published:2024-05-22 Issue:5 Volume:24 Page:631-641
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Chee Cheng Ean¹,Khara Jasmeet Singh²,Cheong John³,Fong Jek³,Sivanesan Sivabalan²,Choy Jian Yi⁴,Hu Meibo⁴,Viswambaram Amrita⁴,Toh Han Chong⁵

Affiliation:

1. Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore

2. Medical, Roche Singapore Pte Ltd, Singapore, Singapore

3. Market Access, Roche Singapore Pte Ltd, Singapore, Singapore

4. Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore

5. Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore

Funder

Roche Singapore Pte Ltd

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2319607

Reference62 articles.

1. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

2. World Health Organization [Internet]. Estimated number of new cases in 2020 liver both sexes all ages. 2020 [cited 2023 May 24]. Available from: https://gco.iarc.fr/today/online-analysis-treemap?v=2018&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=5&group_cancer=1&include_nmsc=1&include_nmsc_other=1&reloaded

3. National Registry of Diseases Office [Internet]. Singapore Cancer Registry Annual Report 2020. 2022 [cited 2023 May 11]. Available from: https://nrdo.gov.sg/docs/librariesprovider3/default-document-library/scr-2020-annual-report_web-release.pdf?sfvrsn=e0a73b99_0

4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

5. National University Hospital [Internet]. Hepatocellular Carcinoma. 2023 [cited 2023 Jul 19]. Available from: https://www.nuhs.edu.sg/For-Patients-Visitors/find-a-condition/Pages/Hepatocellular+Carcinoma.aspx#:~:text=%E2%80%8BThe%20most%20common%20risk hepatitis%20and%20primary%20biliary%20cirrhosis